超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Siemens Oncogene Science 
NCI/NIH scientists established Oncogene Science, Inc. (OSI) in 1983 as a research and development organization focused on cancer and oncogenes. In 1991, OSI acquired Applied bioTechnology of Cambridge MA, which focused on the development and introduction of state-of-the-art diagnostic assays for in vitro diagnostic (IVD) and research-use-only (RUO) applications.
In 1995, OSI sold its Research Products business to CN BioSciences in order to focus resources and efforts within its biopharmaceuticals and diagnostics core competencies. Presently, CN BioSciences operates this business as Oncogene Research Products, and continues to sell antibodies and probes to the research community.
In 1997, Oncogene Science, Inc. changed its name to OSI Pharmaceuticals, Inc. (OSIP), and through a series of corporate partnerships, evolved Oncogene Science Diagnostics, Inc.(OSDI) into a wholly owned subsidiary of OSIP. On December 1, 1999, OSIP sold OSDI to the diagnostics business group of Bayer Corporation. Bayer Corporation is the U.S. holdings of Bayer AG headquartered in Leverkusen, Germany. Bayer, one of the largest medical diagnostics companies in the world, is focused to become the world leader in cancer diagnostics. Effective December 1, 1999, Oncogene Science Diagnostics assumed the trade name Oncogene Science.
Known today as Oncogene Science of Siemens Healthcare Diagnostics Inc., we develop, manufacture, and market high quality, ready-to-use cancer reagent systems for commercial and clinical research customers worldwide. It is our goal to provide novel FDA-cleared oncology assays for the clinical immunodiagnostic market to enhance the care and treatment of cancer patients worldwide as well as lead the way in developing new biomarker assays to further advance oncology care.
Siemens Healthcare Diagnostics Inc.